


**bio-stream**  
When Testing Matters

# Opportunity

- Pre-diabetes
- Infectious disease
- Cardiovascular disease
- Neurodegenerative diseases
- Companion diagnostics
- Water pathogens
- Wellness indicators

**26,000 more biomarkers**



# Test Requirements



- **Blood**
- **Plasma**
- **Serum**
- **Urine**
- **Saliva**
- **Water**
- **Swabs**


- Accurate Results: lab-comparable
- Time to Result: < 5 minutes
- Low-cost consumables: < \$20
- Portable: pocket-sized
- Versatile: many tests created




# Novel Technology




Miniaturized  
SMU & Potentiostat



Advanced Transistor (OECT)



Advanced Multiplexing / Chemistry




# trax Value

**1** Tools to build a bioassay  
(Bio-Stream manufactures)

**2** Royalties paid on 'Consumables'

**3** Same 'Universal' traxReader

**4** FREE app for all End Users



# Projections for Lead Biomarker 'Troponin'



<b>Population</b>	5 million
<b># Tests Performed</b>	600,000

# Troponin Tests

CANADA



3 million

UNITED STATES



30 million

U.K.



7 million

Pop. 440 million

Total **40 million**

# Revenue Sharing of a \$30 test

\$12 wholesale markup (10% of the TAM)

	Number of tests sold	<b>Bioassay Partner</b> 4% Royalty	<b>Commercial Partner</b> 46% Royalty	Retailer
	1	\$0.5	\$5.50	\$7
Single biomarker	4 M	<b>\$2 M /yr</b>	<b>\$22 M /yr</b>	<b>\$28 M /yr</b>
15 biomarkers	60 M	\$30 M /yr	\$330 M /yr	\$420 M /yr

	Number of tests sold	<b>Bio-Stream Revenue</b>
Single biomarker	4 M	<b>\$24 M /yr</b>
15 biomarkers	60 M	\$360 M /yr



# TEAM



**CEO &  
Co-Founder**  
*John Murphy*



**CSO**  
*Dr. Shairaz  
Baksh*



**CTO**  
*Lee Marsh*



**Electrochemical  
Scientist**  
*Erfan  
Rahbarimehr*



**Scientist**  
*Dr. Trevor Allen*



**COO**  
*Don Murphy*



**Software Eng.**  
*Brad Miller*

# BOARD



**Former President:  
NASDAQ**  
*Al Berkeley*



**President &  
Co-Founder**  
*Rashid Bux (BioMark)*



**CEO  
Bio-Stream**  
*John Murphy*



**CEO  
SDMC Inc**  
*Greg Andrukow*

# Competitive Technologies

High Accuracy



*PCR*

*Optical Fluorescence*



*OECT*

*(Organic Electrochemical Transistors)*

Low Cost  
(\$ Hundreds)



*Field Effect transistor  
(FET) Electro-Chemical platforms*



*Lateral Flow with/ without readers*

Low Accuracy

Expensive  
(\$ Thousands)

# INVESTMENT Pre-Series A

**Ask: \$5 million USD (2025)**

## **Use of Funds**

- Volume manufacturing (readers/sensors)
- Inventory (traxReaders)
- Hires – Electrochemical experts, Regulatory, Sales
- Obtain 510K approval (FDA)
- Reach 'Sustainable Revenue'




***We're revolutionizing how people can self-test for their own health issues.***

**THANK YOU**

**John Murphy, CEO**

**[jmurphy@bio-stream.ca](mailto:jmurphy@bio-stream.ca)**



**780-665-1599**



# Technology







# The Technology



# Electrochemical aptamer-based biosensors (EAB) to detect vancomycin


Vancomycin Detection by SWV



Concentration of Vancomycin	Average Signal Gain %	Sensitivity (%)	Specificity (%)	P value (target vs buffer)	N value
25 $\mu$ M (1X PBS)	25.6 $\pm$ 5.2	94	100	< 0.0001	17
25 $\mu$ M (Serum mimic buffer)	39 $\pm$ 4.4	100	100	< 0.0001	5
25 $\mu$ M (in 100% serum)	33.5 $\pm$ 4.7	100	100	< 0.0001	5

# Business Model / Products

# BIO-STREAM CUSTOMERS



**Commercial Partners**  
(Testing companies that own and brand the consumable)






**Health Facilitators (distribution)**

- Physicians in clinics
- Pharmacies
- Nursing homes
- Hospitals
- Health Authorities
- Health Plan Providers



**End Users**  
(Patients)




Testing Company 1  
Testing Company 2  
Testing Company 3






# A UNIVERSAL READER FOR MANY TESTS

Similar to needing only one phone for many apps, the universal traxReader™ is a single device that can be used for many tests, even when the tests are created by different companies.






# From Development to Commercial Product




# Royalties



**Commercialization Partner: 46%**

- All royalty percentages are based on Wholesale Markup



All end users have access to a free mobile app.

Data (test results) are permissioned based.

End users control access to their own data.